What question did this study set out to answer?

The study aims to evaluate TIGIT expression in PDAC and its potential as a target for immunotherapy.

March 13, 2026Cancer Immunology Immunotherapy0 citationsOpen Access

Protein-level profiling of TIGIT axis components in human PDAC reveals immune–suppressive expression patterns

DQDelphine QuatannensUniversity of Antwerp YVYannick VerhoevenUniversity of Antwerp SHSanne van der HeijdenUniversity of Antwerp

Key Points

The study aims to evaluate TIGIT expression in PDAC and its potential as a target for immunotherapy.
Protein-level profiling of TIGIT axis components in human PDAC samples.
Assessment of immune-suppressive expression patterns.
Exploration of dual checkpoint blockade (TIGIT/PD-1) and DNAM-1 signaling restoration.
TIGIT shows immune-suppressive expression patterns in PDAC.
Dual blockade of TIGIT and PD-1 may help overcome immune suppression.
Findings support the rationale for future clinical trials targeting TIGIT.

Abstract

Our findings identify TIGIT as a promising immunotherapeutic target in PDAC and suggest that dual checkpoint blockade (TIGIT/PD-1), alongside restoration of DNAM-1 signaling, may overcome immune suppression. These results provide mechanistic rationale to inform future clinical trials in PDAC.

AI से पूछें

Bookmark

View Full Paper

Cite This Study

Quatannens et al. (Tue,) studied this question.

synapsesocial.com/papers/69b3aca302a1e69014cce7ce https://doi.org/https://doi.org/10.1007/s00262-026-04343-w

AI से पूछें

Bookmark

View Full Paper